<- Go Home

Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.

Market Cap

CHF 35.4B

Volume

762.3K

Cash and Equivalents

CHF 1.3B

EBITDA

CHF 1.6B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

CHF 5.6B

Profit Margin

47.94%

52 Week High

CHF 93.04

52 Week Low

CHF 53.76

Dividend

1.20%

Price / Book Value

3.95

Price / Earnings

55.71

Price / Tangible Book Value

-45.44

Enterprise Value

CHF 39.3B

Enterprise Value / EBITDA

23.74

Operating Income

CHF 1.1B

Return on Equity

7.25%

Return on Assets

3.07

Cash and Short Term Investments

CHF 2.3B

Debt

CHF 6.2B

Equity

CHF 9.0B

Revenue

CHF 11.7B

Unlevered FCF

CHF 1.5B

Sector

Pharmaceuticals

Category

N/A

Company Stock Pitches